Marker Therapeutics, Inc. — Director's Dealing 2021

Jun 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Marker Therapeutics, Inc. (MRKR)
CIK: 0001094038
Period of Report: 2021-06-08

Reporting Person: ELMS STEVE (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-08	Common Stock	A	12658	$0.00	Acquired	29680	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	3142857	Indirect

Footnotes

F1: Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the Company's 2020 Equity Incentive Plan and based on the closing price of $3.16 per share, on the day immediately preceding the date of the Company's 2021 annual meeting.

F2: The reportable securities are directly owned by Aisling Capital IV, LP ("Aisling"), and which may be deemed to be beneficially owned by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms, who have shared voting and dispositive power over the shares. Mr. Elms, the Reporting Person, disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, and the inclusion of these securities herein shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purpose.